Neurocrine Biosciences (NASDAQ:NBIX) had its price objective raised by Needham & Company LLC to $95.00 in a research report report published on Tuesday morning, The Fly reports. The firm currently has a buy rating on the stock.

Several other analysts also recently commented on the stock. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the company an outperform rating in a research report on Thursday, November 2nd. Jefferies Group reiterated a buy rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Oppenheimer set a $85.00 price target on shares of Neurocrine Biosciences and gave the company a buy rating in a research report on Tuesday, December 12th. Leerink Swann reiterated an outperform rating and issued a $83.00 price target (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Barclays upped their price target on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the company an overweight rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of Buy and a consensus price target of $82.31.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down $0.21 during trading on Tuesday, hitting $75.88. 1,135,672 shares of the stock traded hands, compared to its average volume of 1,125,073. Neurocrine Biosciences has a fifty-two week low of $38.43 and a fifty-two week high of $83.84. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. The firm has a market cap of $6,710.00, a PE ratio of -34.18 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter last year, the company earned ($0.43) EPS. analysts expect that Neurocrine Biosciences will post -1.61 earnings per share for the current year.

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the transaction, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Darin Lippoldt sold 1,979 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total transaction of $157,053.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,405 shares of company stock valued at $8,588,519. 4.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. First Trust Advisors LP increased its holdings in shares of Neurocrine Biosciences by 29.0% in the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after purchasing an additional 176,136 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Neurocrine Biosciences by 2.6% in the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after purchasing an additional 140,639 shares in the last quarter. Davidson Kempner Capital Management LP purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at about $3,639,000. Artisan Partners Limited Partnership purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at about $15,981,000. Finally, State Street Corp increased its holdings in shares of Neurocrine Biosciences by 5.1% in the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after purchasing an additional 131,141 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/17/neurocrine-biosciences-nbix-pt-raised-to-95-00.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

The Fly

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related stocks with our FREE daily email newsletter.